A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma

A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma

Objective To explore the efficacy, safety, and factors that might influence the efficacy of antiPD-1 antibody-based therapy in advanced hepatocellular carcinoma in the real world. Methods The clinical features, efficacy, and safety in patients with advanced hepatocellular carcinoma who received anti...

Full description

Bibliographic Details
Main Authors:	QIAO Shishi, KONG Tiandong, YU Dan, YANG Zhen, PAN Yanfeng, ZHAO Lingdi
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2023-03-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	hepatocellular carcinoma anti-pd-1 antibody liver function performance status real world
Online Access:	http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.0852

Similar Items

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01)

Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
by: Jaekyung Cheon, et al.
Published: (2020-07-01)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01)

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
by: Masatoshi Kudo
Published: (2022-05-01)

Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma
by: Xin Hui Chew, et al.
Published: (2021-04-01)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
by: Li Q, et al.
Published: (2022-10-01)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
by: Chenxi Liu, et al.
Published: (2022-07-01)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01)

Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment
by: Ruoxia Wu, et al.
Published: (2023-12-01)

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
by: Vera Himmelsbach, et al.
Published: (2022-03-01)

Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real‐world experience
by: Po‐Ting Lin, et al.
Published: (2023-07-01)

Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
by: Myung Ji Goh, et al.
Published: (2021-01-01)

Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
by: Ming‐Hao Xu, et al.
Published: (2023-04-01)

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
by: Maria Corina Plaz Torres, et al.
Published: (2021-07-01)

Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
by: Ouyang J, et al.
Published: (2023-09-01)

Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
by: Qingwei Zhu, et al.
Published: (2023-02-01)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
by: Shuqun Li, et al.
Published: (2023-02-01)

Risks and Clinical Predictors of Hepatocellular Carcinoma in Chinese Populations: A Real-World Study of 10,359 Patients in Six Medical Centers
by: Huang C, et al.
Published: (2024-02-01)

Corrigendum: Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
by: Shuqun Li, et al.
Published: (2023-04-01)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
by: Guili Huang, et al.
Published: (2022-11-01)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
by: Junwei Kang, et al.
Published: (2022-10-01)

G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma
by: Fei Li, et al.
Published: (2024-01-01)

Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review
by: Bin Liang, et al.
Published: (2023-10-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
by: Amit G. Singal, et al.
Published: (2023-01-01)

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody
by: Bin Xu, et al.
Published: (2022-11-01)

Research on the Clinical Practical Use of Pivoxil-Conjugated Antibodies and the Risk of Carnitine Deficiency Using Real-World Data
by: Kaho Suzuki-Yoshida, et al.
Published: (2024-01-01)

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
by: Armin Scheffler, et al.
Published: (2021-09-01)

Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
by: Rui-Jun Zhang, et al.
Published: (2023-08-01)

Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: Report of two cases
by: Zhenying Xu, et al.
Published: (2023-04-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection
by: Yifei Tan, et al.
Published: (2022-01-01)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
by: Songporn Oranratnachai, et al.
Published: (2023-02-01)

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma
by: WANG Yixin, et al.
Published: (2020-04-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
by: Min Deng, et al.
Published: (2022-12-01)

Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China
by: Chen XQ, et al.
Published: (2022-05-01)

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
by: David Dahlgren, et al.
Published: (2020-06-01)

Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
by: Katharina Kaltseis, et al.
Published: (2023-04-01)